YD Bio Launches a Physician-Partnership Initiative in Taiwan with Two Chrono-Nutrition Formulations
- Aug 11
- 4 min read
Co-developed with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute, this initiative marks our first deployment of a repeatable physician-partnership model in Taiwan.
Taipei, Taiwan, August 11, 2026 — Today, we announced our first physician-partnership initiative in Taiwan with the launch of two chrono-nutrition formulations — a daytime lipid-soluble "Golden Triangle" formula and a nighttime zinc-plus-calcium formula — co-developed with the Taiwan Chronic Disease Healthcare Association ("CDHA") and the Future Health Institute ("FHI"), a physician-led health education platform in Taiwan with more than 233,000 YouTube subscribers.
A Different Kind of Consumer Health Model
Consumer health companies often compete through marketing spend and distribution channels. Our approach starts with physician insights and healthcare relationships.
Practicing physicians identify specific nutritional needs based on observations in their own patient populations. We contribute product development, sourcing, quality oversight, and commercialization expertise. Each product carries the CDHA certification mark and an FHI recommendation — clinical credibility built through established relationships, not purchased attention.
We regard this collaboration with the Taiwan CDHA and FHI as the initial deployment of a repeatable physician-partnership model, rather than a standalone product launch. We intend to explore additional collaborations with other physicians and healthcare organizations over time.
Launch Highlights
Daytime: Lipid-Soluble "Golden Triangle" Formula
A daytime formulation built around lipid-soluble nutrients, co-developed with practicing physicians and certified by the Taiwan CDHA.
Nighttime: Zinc-Plus-Calcium Formula
A nighttime formulation designed to complement the body's overnight recovery processes, co-developed with practicing physicians and certified by the Taiwan CDHA.
Both formulations are launched under the YD Bio brand and carry an FHI recommendation.
Why a Physician-Partnership Model
We believe this approach offers three advantages:
(1) Healthcare solutions grounded in observed patient needs — formulations are defined by clinicians based on what they see in their own patient populations, not by marketing trends.
(2) Distribution through established trust — products reach consumers through physician relationships built over time, not through paid advertising.
(3) A repeatable template — the model is designed to be applied again with each new physician partner, across different patient communities and health needs.
For YD Bio, this model is intended to be capital-light relative to our therapeutic and diagnostic programs, to generate recurring consumer revenue, and to build a relationship with health-conscious consumers in Taiwan that may support future engagement with our regulated diagnostics and clinical services.
Scientific Background
The daytime formulation reflects an area of research interest for our scientific team. A review manuscript titled "Beyond Bone Health: Exploring the 'Heart-Brain-Bone' Axis Modulated by Lipid-Soluble Nutrients (Omega-3, Vitamin D3, and Vitamin K2)," co-authored by YD Bio personnel together with physician-researchers in Taiwan, has been submitted to a peer-reviewed journal and is currently under review. This manuscript is a narrative review and has not been peer-reviewed or accepted for publication. It does not establish the clinical safety or efficacy of any product.
Leadership Commentary
"Our vision is to build an integrated healthcare platform that connects scientific innovation, clinical expertise and patient needs," said Dr. Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio. "Our collaboration with physician-led organizations in Taiwan represents an important step in expanding our healthcare ecosystem and building trusted relationships with healthcare professionals and consumers. While consumer health products represent one component of our broader strategy, our focus remains on developing scalable healthcare solutions across diagnostics, clinical services and life science commercialization."
About YD Bio Limited
YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. We operate DNA methylation-based oncology testing programs in the United States under a laboratory-developed test strategy and support pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, we maintain regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.
Forward-Looking Statements
This article contains forward-looking statements, including statements regarding our intention to co-develop additional products with further physician partners, the anticipated benefits and repeatability of the physician-partnership model, the expected contribution of consumer health activities to our business, and the submission and potential publication of the review manuscript submitted to a peer-reviewed journal. Forward-looking statements are not guarantees of future performance. The manuscript described above is a narrative review, has not been peer-reviewed or accepted for publication, and does not establish the clinical safety or efficacy of any product. Actual results may differ materially due to a variety of factors, including consumer demand and market acceptance, our ability to enter into and maintain partnerships with physicians and other healthcare organizations, supply chain disruptions, manufacturing and quality considerations, competition, and regulatory and labeling requirements in Taiwan and other jurisdictions. We undertake no obligation to update any forward-looking statements, except as required by law.
For investor and media inquiries, please contact:
YD Bio Limited Investor Relations
Email: investor@ydesgroup.com
WFS Investor Relations Inc.
Phone: +1 628 283 9214
